Cosmetic cross-reference

Eucalyptol

CAS 470-82-6

Eucalyptol (CAS 470-82-6) is a Phase 3 pharmaceutical compound with 6 bioactivity targets and 5 adverse event associations.

SOURCE NLM DailyMed
Label records
1
SOURCE EMBL-EBI ChEMBL
Bioactivity
6
SOURCE DrugCentral
Adverse signals
5
SOURCE IUPHAR/BPS
PubMed IDs
2
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Eucalyptol
CAS Number
470-82-6
UNII
RV6J6604TK
InChIKey
WEEGYLXZBRQIMU-UHFFFAOYSA-N
ChEMBL ID
CHEMBL485259
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL485259 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE NLM DailyMed 1 label row

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
Antispetic EUCALYPTOL
RV6J6604TK
 EUCALYPTOL 20260505
SOURCE EMBL-EBI ChEMBL 6 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- GI50 33566.79046153846 nM 65 -
- Potency 23575.342857142856 nM 14 -
- MIC 800 ug.mL-1 12 -
- IC50 14988.154999999999 nM 3 -
- EC50 50 microg/cm2 2 -
- AC50 12589.3 nM 1 -
SOURCE DrugCentral 2 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Product prescribing error 17 42.015 10081770
Dyspnoea 45 29.501 10013968

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 2 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
TRPM8
Trpm8
 Partial agonist 2.1 pEC50 14757700
TRPM8
Trpm8
 Partial agonist 2.5 pEC50 11882888
SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Eucalyptol 21116 SU MTHSPL
EUCALYPTOL 21116 SU MTHSPL
eucalyptol 21116 SU MTHSPL
eucalyptol 21116 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Eucalyptol used for in pharmaceutical contexts?

Eucalyptol (CAS 470-82-6) appears in DailyMed active-ingredient label rows, including Antispetic.

What are the known adverse events for Eucalyptol?

Eucalyptol has 5 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Product prescribing error, Dyspnoea, Blood urine present, Haematochezia, Platelet count decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Eucalyptol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Eucalyptol Cosmetic with EU status "permitted".

What clinical phase is Eucalyptol in?

Eucalyptol is rendered with ChEMBL max phase 3.